Preparing for Biosimilars

Manufacturers of biologic drugs over the past few years have been “pulling out all the stops” to make it difficult for less expensive biosimilar products to come to market.  Biologic drug manufactures have used tactics like patent infringement suits to delay the availability of biosimilars.

Note: Biosimilars are the “generic” equivalent of a biologic drug.  Unlike traditional drugs, biologics are made from living cells and cannot be copied exactly to make generic versions. They are used to treat a range of conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque psoriasis, breast cancer and diabetes. 

The U.S. Supreme Court, in a recent 9-0 ruling, reduced one of the barriers for biosimilars by overturning a lower court’s decision that had prevented biosilimar drugs from coming to market quickly.

For example, Novartis, the Swiss pharmaceutical company, has been prevented from marketing a biosimilar of California-based Amgen’s Neupogen until six months after the U.S. Food and Drug Administration (FDA) approved it.

More Recent Posts

CSS is at AMCP Nexus 2018

CSS is at AMCP Nexus 2018

We're in Orlando for AMCP Nexus from October 22 - 25. Stop by to visit at at Booth 508 to talk about what matters to you in the world of MTM. At our... Continued

Continue Reading
Patient Acceptance of Pharmacist Run Transition of Care Service

Patient Acceptance of Pharmacist Run Transition of Care Service

A recent article in Innovations in Pharmacy, describes a unique pharmacy based transition of care service. Kowalski et. al. describe a transitions of... Continued

Continue Reading
Are ACOs Prepared to Managed Medication Quality and Cost

Are ACOs Prepared to Managed Medication Quality and Cost

BACKGROUND Recentlt Wilks et. al published Optimization of Medication Use at Accountable Care Organizations.The authors studied accountable care... Continued

Continue Reading